ABSTRACT
The aim of this study was to assess the immunohistochemical expression of syndecan-1 (CD138) and Ki-67 in radicular cysts (RC), dentigerous cysts (DC) and keratocystic odontogenic tumors (KOT). Thirty-five RC, 22 DC and 17 KOT were used in the study and immunohistochemical reactions using anti-syndecan-1 and anti-Ki-67 antibodies were performed by the streptavidin-biotin-peroxidase method. Fisher's exact test and Spearman's correlation coefficient were used for statistical analysis of data. Among the studied lesions, no differences in the syndecan-1 expression were observed, but the suprabasal expression of Ki-67 was significantly higher in KOT (p<0.0001), when compared with RC and DC. In RC, there was positive correlation between the expression (p=0.02) and intensity (p=0.0001) of syndecan-1 and between the intensity of syndecan-1 and Ki-67 expression (p=0.01). In the KOT, Ki-67 expression in the suprabasal layer correlated positively with the expression (p=0.01) and intensity (p=0.01) of syndecan-1. The expression of syndecan-1 does not seem to be a determinant factor of the distinct histopathological features and biological behavior of the studied lesions. Nevertheless, positive correlation between syndecan-1 and a cell proliferation marker was observed in RC and KOT.
O objetivo deste estudo foi avaliar a expressão imunoistoquímica de syndecan-1 (CD138) e Ki-67 em cistos radiculares (CR), cistos dentígeros (CD) e tumores odontogênicos queratocísticos (TOQ). Trinta e cinco CR, 22 CD e 17 TOQ foram utilizados no estudo e as reações imunoistoquímicas usando os anticorpos anti-syndecan-1 e anti-Ki-67 foram realizadas pelo método estreptavidina-biotina-peroxidase. Para análise estatística, o teste exato de Fisher e o coeficiente de correlação de Spearman foram utilizados. Entre as lesões estudadas, não foram observadas diferenças na expressão de syndecan-1, mas a expressão suprabasal de Ki-67 foi significativamente maior nos TOQ (p<0,0001), quando comparado aos CR e CD. No CR, havia correlação positiva entre a expressão (p=0,02) e intensidade (p=0,0001) de syndecan-1 e entre a intensidade de syndecan-1 e expressão de Ki-67 (p=0,01). No TOQ, a expressão de Ki-67 na camada suprabasal correlacionou positivamente com a expressão (p=0,01) e intensidade de expressão (p=0,01) de syndecan-1. A expressão de syndecan-1 não parece ser um fator determinante das características histopatológicas distintas e do comportamento biológico das lesões estudadas. Entretanto, correlação positiva entre syndecan-1 e um marcador de proliferação celular foi evidenciado em CR e TOQ.
Subject(s)
Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Young Adult , /analysis , Odontogenic Cysts/pathology , Odontogenic Tumors/pathology , Syndecan-1/analysis , Antibodies , Cell Proliferation , Dentigerous Cyst/pathology , Epithelial Cells/pathology , Epithelium/pathology , Immunoenzyme Techniques , Immunohistochemistry , Mandibular Diseases/pathology , Mandibular Neoplasms/pathology , Maxillary Diseases/pathology , Retrospective Studies , Radicular Cyst/pathologyABSTRACT
Syndecans, a family of heparan sulphate proteoglycans that are present in the cellsurface are involved in the control o fcel lproliferation, apoptosis and transfor-mation. Syndecans 1 and 2 have a central role in processes such as position control, invasion, angiogenesis and metastases ofseveral types of cáncer The expression of Syndecan 1 in epithelial cells, decreases when cells are transformed and acquire invasive properties. This decreased expression is associated to a bad prognosis. Syndecan 2, originally described in mesenchymal cells, favors cell apoptosis, increa-ses angiogenesis and controls the death of cáncer cells subjected to chemotherapy Both syndecans are present in basal and epithelial cells of prostate cancer Their lower expression is associated to more undifferentiated tumors. Disturbances in the expression and subcellular location of syndecans predict the relapse of localized tumors. Syndecans 1 and 2 can be considered tumor suppression genes and can be targetsfor new treatments. The detection of circulating fragments of these molecules could be useful for the early detection of prostate cancer.
Subject(s)
Humans , Male , Prostatic Neoplasms/diagnosis , Syndecan-1/metabolism , /metabolism , Biomarkers, Tumor/metabolism , Prognosis , Syndecan-1/analysis , /analysis , Biomarkers, Tumor/analysisABSTRACT
We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre. Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL). Most of the PBL are extranodal in location and are mucosa-based. We reviewed the morphological features of 34 cases of PBL. Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based). We classified PBL into three morphological subtypes (immunoblastic - 25, Burkitt's - 7, plasmacytic - 2). Tumor cells expressed as leucocyte common antigen (LCA) in 60%, CD138 in 100%, EMA in 45% and light chain restriction in 86% cases. CD20 was negative in all cases. Pathologists need to be aware of PBL and its various morphological subtypes as the identification of this entity from its close differentials carries major therapeutic implications.